Citations

Mayo Clinic

Clear

1458 citation(s) found for "Wu, Sean M".

Implicit and explicit weight bias in a national sample of 4,732 medical students: The medical student CHANGES study
Dovidio, John F. , Puhl, Rebecca M. , Nelson, David , Yeazel, Mark W. , Perry, Sylvia , Ryn, Michelle van , Phelan, Sean M. , Burgess, Diana Jill , Hardeman, Rachel R. , Perry, Sylvia P , van Ryn, Michelle

Obesity | December 23, 2013 | Volume: 22 | Issue: 4 | Pages: 1201-1208

10.1002/oby.20687 | PMID 24375989 Get It

ObjectiveTo examine the magnitude of explicit and implicit weight biases compared to biases against other groups; and identify student factors predicting bias in a large national sample of medical students.MethodsA web‐based survey was completed by 4,732 1st year medical students from 49 medical schools as part of a longitudinal study of medical education. The survey included a validated measure of implicit weight bias, the implicit association test, and 2 measures of explicit bias: a feeling thermometer and the anti‐fat attitudes test.ResultsA majority of students exhibited implicit (74%) and explicit (67%) weight bias. Implicit weight bias scores were comparable to reported bias against racial minorities. Explicit attitudes were more negative toward obese people than toward racial minorities, gays, lesbians, and poor people. In multivariate regression models, implicit and explicit weight bias was predicted by lower BMI, male sex, and non‐Black race. Either implicit or explicit bias was also predicted by age, SES, country of birth, and specialty choice.ConclusionsImplicit and explicit weight bias is common among 1st year medical students, and varies across student factors. Future research should assess implications of biases and test interventions to reduce their impact.
Isolated Arthroscopic Rotator Interval Closure for Shoulder Instability
Krych, Aaron J. , Shindle, Michael K., Baran, Sean, Warren, Russell F. , Krych, Aaron J

Arthroscopy Techniques | December 14, 2013 | Volume: 3 | Issue: 1 | Pages: No page available

10.1016/j.eats.2013.08.010 | PMID 24749020 Get It

Abstract We present our technique for isolated arthroscopic rotator interval closure in the treatment of mild symptomatic glenohumeral instability in the absence of a labral tear. A careful history, physical examination, and imaging help to identify a select subset of atraumatic instability patients who may benefit from this procedure, and diagnostic arthroscopy can provide further evidence. By use of a posterior viewing portal with anterior and anterolateral working portals, the anterior capsuloligamentous complex is mobilized, and the rotator interval is closed with carefully placed sutures to advance the capsule superiorly and provide tension through decreased capsular volume. Technique Video video See video under supplementary data.
Transesophageal Echocardiographic Imaging of Ultrasound Lung Rockets
Rehfeldt, Kent H., Bruggink, Sean M., Pulido, Juan N.

Anesthesiology | December 9, 2013 | Volume: 121 | Issue: 6 | Pages: 1335-1335

10.1097/aln.0000000000000098 | PMID 25409196 Get It

HE4 Transcription- and Splice Variants-Specific Expression in Endometrial Cancer and Correlation with Patient Survival
Jiang, Shi-Wen, Chen, Hai-Bin , Dowdy, Sean C. , Fu, Alex Z., Attewell, John R., Kalogera, Eleftheria , Drapkin, Ronny , Podratz, Karl C. , Broaddus, Russell R. , Li, Jinping , Jiang, Shi‐Wen , Drapkin, Ronny

International Journal of Molecular Sciences | November 19, 2013 | Volume: 14 | Issue: 11 | Pages: 22655-22677

10.3390/ijms141122655 | PMID 24252907 Get It

We investigated the HE4 variant-specific expression patterns in various normal tissues as well as in normal and malignant endometrial tissues. The relationships between mRNA variants and age, body weight, or survival are analyzed. ICAT-labeled normal and endometrial cancer (EC) tissues were analyzed with multidimensional liquid chromatography followed by tandem mass spectrometry. Levels of HE4 mRNA variants were measured by real-time PCR. Mean mRNA levels were compared among 16 normal endometrial samples, 14 grade 1 and 14 grade 3 endometrioid EC, 15 papillary serous EC, and 14 normal human tissue samples. The relationship between levels of HE4 variants and EC patient characteristics was analyzed with the use of Pearson correlation test. We found that, although all five HE4 mRNA variants are detectable in normal tissue samples, their expression is highly tissue-specific, with epididymis, trachea, breast and endometrium containing the highest levels. HE4-V0, -V1, and -V3 are the most abundant variants in both normal and malignant tissues. All variants are significantly increased in both endometrioid and papillary serous EC, with higher levels observed in grade 3 endometrioid EC. In the EC group, HE4-V1, -V3, and -V4 levels inversely correlate with EC patient survival, whereas HE4-V0 levels positively correlate with age. HE4 variants exhibit tissue-specific expression, suggesting that each variant may exert distinct functions in normal and malignant cells. HE4 levels appear to correlate with EC patient survival in a variant-specific manner. When using HE4 as a biomarker for EC management, the effects of age should be considered.
Aquaporin 4 IgG Serostatus and Outcome in Recurrent Longitudinally Extensive Transverse Myelitis
Jiao, Yujuan , Fryer, James P., Lennon, Vanda A. , McKeon, Andrew , Jenkins, Sarah M. , Quek, Amy May Lin, Weinshenker, Brian G. , Wingerchuk, Dean M. , Shuster, Elizabeth A., Lucchinetti, Claudia F. , Pittock, Sean J. , Smith, Carin Y. , Quek, Amy M L, Pittock, S J , Weinshenker, Brian G , McKeon, Andrew , Quek, Amy M.L.

JAMA Neurology | November 18, 2013 | Volume: 71 | Issue: 1 | Pages: 48

10.1001/jamaneurol.2013.5055 | PMID 24248262 Get It

APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma
Leonard, Brandon , Hart, Steven N. , Burns, Michael B. , Carpenter, Michael A. , Temiz, Nuri A. , Vogel, Rachel I. , Nikas, Jason B. , Brown, William L. , Zhang, Yuji , Maurer, Matthew J. , Oberg, Ann L. , Cunningham, Julie M. , Shridhar, Viji , Bell, Debra A., April, Craig, Bentley, David, Bibikova, Marina, Cheetham, R. Keira, Fan, Jian‐Bing , Grocock, Russell, Humphray, Sean, Kingsbury, Zoya, Peden, John F., Chien, Jeremy , Swisher, Elizabeth M. , Hartmann, Lynn C. , Kalli, Kimberly R., Goode, Ellen L. , Sicotte, Hugues , Rathore, Anurag Singh , Law, Emily K. , Li, Ying , Kaufmann, Scott H. , Harris, Reuben S. , Maurer, Matthew , Chien, Jeremey , Swisher, Elizabeth M , Vogel, Rachel I , Hart, Steven N , Temiz, Nuri A

Cancer Research | October 24, 2013 | Volume: 73 | Issue: 24 | Pages: 7222-7231

10.1158/0008-5472.can-13-1753 | PMID 24154874 Get It

Abstract Ovarian cancer is a clinically and molecularly heterogeneous disease. The driving forces behind this variability are unknown. Here, we report wide variation in the expression of the DNA cytosine deaminase APOBEC3B, with elevated expression in the majority of ovarian cancer cell lines (three SDs above the mean of normal ovarian surface epithelial cells) and high-grade primary ovarian cancers. APOBEC3B is active in the nucleus of several ovarian cancer cell lines and elicits a biochemical preference for deamination of cytosines in 5′-TC dinucleotides. Importantly, examination of whole-genome sequence from 16 ovarian cancers reveals that APOBEC3B expression correlates with total mutation load as well as elevated levels of transversion mutations. In particular, high APOBEC3B expression correlates with C-to-A and C-to-G transversion mutations within 5′-TC dinucleotide motifs in early-stage high-grade serous ovarian cancer genomes, suggesting that APOBEC3B-catalyzed genomic uracil lesions are further processed by downstream DNA "repair" enzymes including error-prone translesion polymerases. These data identify a potential role for APOBEC3B in serous ovarian cancer genomic instability. Cancer Res; 73(24); 7222–31. ©2013 AACR.
Dual HER/VEGF Receptor Targeting Inhibits In Vivo Ovarian Cancer Tumor Growth
Becker, Marc A., Farzan, Thahir, Harrington, Sean C., Krempski, James , Weroha, S. John , Hou, Xiaonan , Kalli, Kimberly R., Wong, Tai W., Haluska, Paul , Krempski, James W

Molecular Cancer Therapeutics | October 16, 2013 | Volume: 12 | Issue: 12 | Pages: 2909-2916

10.1158/1535-7163.mct-13-0547 | PMID 24130056 Get It

Abstract Ovarian cancer mortality ranks highest among all gynecologic cancers with growth factor pathways playing an integral role in tumorigenesis, metastatic dissemination, and therapeutic resistance. The HER and VEGF receptor (VEGFR) are both overexpressed and/or aberrantly activated in subsets of ovarian tumors. While agents targeting either the HER or VEGF pathways alone have been investigated, the impact of these agents have not led to overall survival benefit in ovarian cancer. We tested the hypothesis that cotargeting HER and VEGFR would maximize antitumor efficacy at tolerable doses. To this end, ovarian cancer xenografts grown intraperitoneally in athymic nude mice were tested in response to AC480 (pan-HER inhibitor, “HERi”), cediranib (pan-VEGFR inhibitor “VEGFRi”), or BMS-690514 (combined HER/VEGFR inhibitor “EVRi”). EVRi was superior to both HERi and VEGFRi in terms of tumor growth, final tumor weight, and progression-free survival. Correlative tumor studies employing phosphoproteomic antibody arrays revealed distinct agent-specific alterations, with EVRi inducing the greatest overall effect on growth factor signaling. These data suggest that simultaneous inhibition of HER and VEGFR may benefit select subsets of ovarian cancer tumors. To this end, we derived a novel HER/VEGF signature that correlated with poor overall survival in high-grade, late stage, serous ovarian cancer patient tumors. Mol Cancer Ther; 12(12); 2909–16. ©2013 AACR.
P4–086: Dramatic improvement with donepezil in a case of dementia with Lewy bodies
Allen, Laura A., Josephs, Keith A. , Ivnik, Robert J., Lowe, Val J. , Pittock, Sean J. , Smith, Glenn E. , Boeve, Bradley F.

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_18 | Pages: No page available

10.1016/j.jalz.2013.05.1475 Get It

Utility of multimodal analgesia with fascia iliaca blockade for acute pain management following hip arthroscopy
Krych, Aaron J. , Baran, Sean, Kuzma, Scott A., Smith, Hugh M. , Levy, Bruce A. , Johnson, Rebecca L. , Krych, Aaron J

Knee Surgery, Sports Traumatology, Arthroscopy | September 23, 2013 | Volume: 22 | Issue: 4 | Pages: 843-847

10.1007/s00167-013-2665-y | PMID 24061718 Get It

AbstractPurposeThe purpose of this study was to evaluate the utility of multimodal analgesia with fascia iliaca blockade and for acute pain control in patients undergoing hip arthroscopy.MethodsThirty consecutive patients undergoing primary hip arthroscopy were prospectively studied. All patients were treated preoperatively with ultrasound‐guided single injection fascia iliaca blockade and multimodal analgesia. Data collected included post‐operative nausea, numeric rating scale (NRS) pain scores during rest and activity, opioid consumption during the first five days (recorded as tablets of 5 mg hydrocodone/500 mg acetaminophen) and overall patient satisfaction with analgesia.ResultsThis study included 23 female and 7 male patients with a median age of 35 years (range 14–58). No patient required medication for post‐operative nausea. The overall NRS scores were an average of 3.9 on day 0, 3.6 on day 1, 3.4 on day 2, 2.9 on day 3, 3.0 on day 4 and 2.7 on day 5. The average tablets of opioid taken were 1.5 on day 0, 1.2 on day 1, 1.3 on day 2, 1.0 on day 3, 1.1 on day 4 and 0.9 on day 5. Overall, 20 patients rated their post‐operative pain control as very satisfied (67 %), and 10 patients as satisfied (33 %). There were no complications or side effects from the fascia iliaca blockade.ConclusionIn this prospective study, multimodal analgesia with fascia iliaca blockade following hip arthroscopy was safe and effective. The quality of early post‐operative analgesia provided by the fascia iliaca blockade was excellent and resulted in low opioid consumption, high quality of pain relief and high overall patient satisfaction.Level of evidenceProspective case series, Level II.